Loading stock data…
BMRN
$54.60+1.36 (+2.55%)
Pre-Market$54.60+0.00 (+0.00%)· Last close May 6
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
BioMarin Pharmaceutical Inc. in the Healthcare sector is trading at $54.60. The stock is currently 18% below its 52-week high of $66.28, remaining 3.1% below its 200-day moving average. Technical signals show neutral RSI of 53 and bullish MACD crossover, explaining why BMRN maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 53) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$54.60
Potential Downside
32.8%
Whystock Fair Value$36.70
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus24 analysts
Buy
Mean target$90.13+65.1%
Range$55.00 – $120.00
Fundamentals
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Paci...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$10.43B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
29.99
Beta
Defensive asset. Lower volatility than the S&P 500.
0.29
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
10.80%
Volume
Today's trading volume
2.36M
Recent News
Is BioMarin Pharmaceutical (BMRN) Pricing Reflect Its Rare Disease Growth And Voxzogo Prospects
For investors considering whether BioMarin Pharmaceutical is starting to look like value or a value trap, this article walks through what the current share price might be implying about the stock. The stock closed at US$53.24, with returns of 0.1% over 7 days, 4.1% over 30 days, 10.4% year to date, 10.7% over 1 year, 44.3% over 3 years and 29.7% over 5 years. This provides a useful backdrop before getting into valuation. Recent coverage of BioMarin Pharmaceutical has focused on its position...
BioMarin Q1 Earnings Miss, Sales Beat, '26 Revenue Guidance Raised
BMRN misses Q1 EPS estimates despite a revenue beat, as charges and higher costs weigh on profits, while new Amicus deal lifts the 2026 outlook.
BioMarin Pharmaceutical Q1 Revenue Beat Backed by Voxzogo Strength, Diversified Portfolio, Wedbush Says
BioMarin Pharmaceutical (BMRN) reported a Q1 beat on revenue, driven by Voxzogo and continued portfo
BioMarin Enters 'Transition Year' as Enzyme Portfolio Expands After Amicus Deal, Morgan Stanley Says
BioMarin Pharmaceutical (BMRN) is entering a "transition year" in 2026, prioritizing growth accelera
BioMarin Pharmaceutical Inc. Q1 2026 Earnings Call Summary
Moby summary of BioMarin Pharmaceutical Inc.'s Q1 2026 earnings call